Malter A D, Larson E B, Urban N, Deyo R A
University of Washington School of Public Health, Seattle, USA.
Spine (Phila Pa 1976). 1996 May 1;21(9):1048-54; discussion 1055. doi: 10.1097/00007632-199605010-00011.
A cost-effectiveness analysis of lumbar discectomy based on existing efficacy data and newly gathered cost data.
For patients with herniated lumbar discs unresponsive to conservative management, surgery relieves pain more rapidly but at higher costs than continued medical therapy. We evaluated the cost-effectiveness of lumbar discectomy for these patients.
Effectiveness estimates were based on the results of a published trial of 126 herniated disc patients randomized to surgical or nonsurgical treatment. Quality of life values were based on a study of 83 subjects with low back pain. Treatment costs for herniated discs were estimated from insurance data for 372 patients treated surgically and 1,803 treated medically.
Efficacy results were weighted by quality of life values to estimate the quality-adjusted benefit of surgery. Cost-effectiveness was calculated in dollars per quality-adjusted year of life gained. Supplemental data sources for cost and effectiveness provided ranges for sensitivity analyses.
Surgery increased average quality-adjusted life expectancy by 0.43 years during the decade following treatment, a benefit similar to extending a healthy life by 5 months. Reimbursements for surgical patients were $12,550 more than for medical patients. Nondiscounted and 5% discounted cost-effectiveness were $29,200 and $33,900 per quality-adjusted year of life gained. Supplemental analyses confirmed the basecase effectiveness estimates but suggested that the cost of discectomy was overestimated. Replacing the main cost estimate with one based on HMO patients lowered discectomy's cost to $12,000 per quality-adjusted life-year gained.
For carefully selected patients with herniated discs, surgical discectomy is a cost-effective treatment. Discectomy's favorable cost-effectiveness results from its substantial effect on quality of life and moderate costs.
基于现有疗效数据和新收集的成本数据对腰椎间盘切除术进行成本效益分析。
对于经保守治疗无效的腰椎间盘突出症患者,手术能更快缓解疼痛,但成本高于持续的药物治疗。我们评估了这些患者接受腰椎间盘切除术的成本效益。
疗效评估基于一项已发表的试验结果,该试验将126例椎间盘突出症患者随机分为手术治疗组或非手术治疗组。生活质量值基于对83例腰痛患者的研究。椎间盘突出症的治疗成本根据372例接受手术治疗患者和1803例接受药物治疗患者的保险数据估算得出。
疗效结果通过生活质量值加权,以估算手术的质量调整效益。成本效益按每获得一个质量调整生命年的美元数计算。成本和效益的补充数据源为敏感性分析提供了范围。
治疗后的十年中,手术使平均质量调整预期寿命增加了0.43年,这一效益类似于将健康寿命延长5个月。手术患者的报销费用比药物治疗患者多12,550美元。未贴现和5%贴现的成本效益分别为每获得一个质量调整生命年29,200美元和33,900美元。补充分析证实了基线疗效评估,但表明椎间盘切除术的成本被高估。用基于健康维护组织(HMO)患者的成本估算取代主要成本估算后,每获得一个质量调整生命年,椎间盘切除术的成本降至12,000美元。
对于精心挑选的椎间盘突出症患者,手术椎间盘切除术是一种具有成本效益的治疗方法。椎间盘切除术良好的成本效益源于其对生活质量的显著影响和适度的成本。